Markets
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Reata Pharmaceuticals (RETA – Research Report) on April 26. The company’s shares closed last Wednesday at $103.79.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 15.9% and a 49.6% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reata Pharmaceuticals with a $186.33 average price target, implying an 82.4% upside from current levels. In a report issued on April 26, Barclays also initiated coverage with a Buy rating on the stock with a $155.00 price target.